| Theme | The State of the Art in Chemotherapy for Gastrointestinal Cancer | |
|---|---|---|
| Title | Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma : Current Status and Future Perspectives | |
| Publish Date | 2011/06 | |
| Author | Masato Ozaka | Department of Gastroenterology, Cancer Institute Ariake Hospital |
| Author | Hiroshi Ishii | Department of Gastroenterology, Cancer Institute Ariake Hospital |
| [ Summary ] | Sorafenib is the first drug found to prolong survival of patients with advanced hepatocellular carcinoma (HCC). The approval of sorafenib as the first effective drug for the treatment of HCC represents a milestone in the treatment of this disease. This review describes the evidence related to sorafenib, explores current and future treatments, and describes how these new therapies may augment existing approaches to HCC treatment. | |